Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

We recently published 11 Best Cancer Stocks to Buy Right NowGenmab A/S is placed ninth among the best cancer stocks.

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma and epcoritamab for B-cell malignancies. Strategic partnerships with AbbVie and Johnson & Johnson support the company’s expanded oncology portfolio and commercialization efforts.

At ASCO 2025, Genmab A/S (NASDAQ:GMAB) presented key data highlighting its pipeline progress. Early results from a Phase 1/2 trial of Rina-S, a folate receptor-alpha targeted antibody-drug conjugate (ADC) for advanced endometrial cancer, showed promise in addressing this hard-to-treat women’s cancer. Long-term follow-up from the EPCORE NHL-1 study demonstrated durable complete responses at two years for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), underscoring its potential as a core therapy alongside AbbVie.

The company also reported positive Phase 3 EPCORE FL-1 results for epcoritamab in follicular lymphoma, where combination therapy with rituximab and lenalidomide achieved a 95.7% overall response rate and reduced the risk of progression by 79%, further strengthening its position among the best cancer stocks in the immuno-oncology space.

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

A laboratory technician using high tech equipment to sequence cancer genomics.

In May 2025, the business expanded its ADC capabilities through a $1.8 billion acquisition of ProfoundBio, adding next-generation ADC candidates to accelerate the development of transformative cancer treatments. The company continues to advance innovative platforms such as DuoBody and HexaBody, as well as research into immune complement system modulation, aimed at improving therapeutic efficacy and safety.

While we acknowledge the risk and potential of GMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GMAB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.